A customer from the overseas department of Réunion Island, France, consulted our company regarding peptide products. During the initial contact, the customer mainly inquired about the specific procedures, timeliness, and stability of international transportation, and voluntarily stated that they would use the registered mobile phone number in Vietnam as the means for subsequent communication and placing orders. A few days later, the customer contacted again, clearly requesting that we provide a formal quotation for the combined product of CJC-1295 Without DAC (5mg) and IPA (Iparomine, 5mg). During the quotation process, when the customer learned that the shipping fee was $85, they initially expressed that they could not accept it, considering the cost to be too high. I then patiently explained that this fee was not merely for shipping costs, but a comprehensive service price that included the cost of professional temperature-controlled packaging materials in accordance with the standards for transporting biological products, the international air freight logistics costs from China to Réunion, and the most crucial assistance service for destination import customs clearance to ensure the product was legally and smoothly delivered. After the customer clearly understood the composition and value of the fees, their doubts were dispelled, and their attitude turned to a willing acceptance. They immediately completed the order payment, and the entire communication process was professional and smooth, ultimately successfully concluding the transaction.
|
|
|
|
|
|
|
|
CJC-1295 Without DAC: The "Switch" for Long-Acting Growth Hormone Release
Core Mechanism
CJC-1295 Without DAC is an artificially synthesized growth hormone-releasing hormone (GHRH) analogue consisting of 30 amino acids. Its mechanism of action is to activate the growth hormone-releasing receptor in the anterior pituitary gland by mimicking natural GHRH, thereby promoting the secretion of endogenous growth hormone (GH). Compared to natural GHRH, the molecular structure of CJC-1295 Without DAC has been optimized, with its half-life extended to approximately 30 minutes (while natural GHRH has a half-life of only 10-20 minutes), but it still requires 1-3 daily injections to maintain a stable effect.
Key Features
Without DAC (Drug Affinity Complex): DAC is a technology that extends the half-life of a drug by binding to albumin in the blood. CJC-1295 Without DAC does not add DAC, so its duration of action is closer to the physiological rhythm, making it suitable for simulating the natural pulse release of GH at night.
Molecular weight and structure: The molecular weight is 3367.897, composed of amino acids such as tyrosine (Tyr), D-alanine (D-Ala), aspartic acid (Asp), etc., and the sequence is: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys
Solubility and Storage: Slightly soluble in water, ethanol, and methanol. It should be stored in an inert gas environment at -20℃ to prevent degradation.
Clinical Applications
Promote muscle growth and repair: By increasing the levels of GH and insulin-like growth factor-1 (IGF-1), it enhances protein synthesis and promotes an increase in muscle volume and strength.
Reduce fat accumulation: GH can activate fat-decomposing enzymes, accelerate fat oxidation metabolism, and lower body fat percentage.
Improve sleep quality: GH secretion is closely related to deep sleep (slow-wave sleep), and CJC-1295 Without DAC can help regulate sleep cycles and improve recovery efficiency.
Anti-aging potential: Long-term use may improve bone density, immune function and skin elasticity, but more research is needed to confirm this.
Usage plan
Dosage: 1-3 times per day, 100-200 μg (1-2 mg/week). The dosage should be adjusted according to individual responses.
Injection method: Subcutaneous injection. The common injection sites are the abdomen or the outer side of the thigh.
Cycle management: It is recommended to have a 3-month "hormone break" every 3-6 months to avoid suppression of the pituitary function.
IPA (Ipamorelin): A "short-acting catalyst" for precisely activating GH
Core mechanism
IPA is a selective growth hormone releasing hormone (GHS) that promotes GH secretion by activating the GHSR on the hypothalamus-pituitary axis. Unlike CJC-1295 Without DAC, IPA has a shorter duration of action (half-life approximately 2 hours), but it is more specific and has almost no effect on prolactin, cortisol, and other hormone levels, with fewer side effects.
Key Features
Molecular weight and structure: The molecular weight is 711.86, consisting of 5 amino acids, and the sequence is: Aib-His-D-2-Nal-D-Phe-Lys-NH2
(Aib stands for α-amino isobutyric acid, 2-Nal for 2-naphthylalanine)
Solubility and storage: Soluble in water and should be stored at -20℃.
Clinical applications
Synergistic efficacy: When used in combination with CJC-1295 without DAC, it can cover the "pulse peak" and "basal value" of GH secretion, achieving continuous release for 24 hours.
Reduction of side effects: IPA does not significantly increase gastric acid secretion or appetite, making it suitable for long-term use.
Improvement of athletic performance: By enhancing GH and IGF-1 levels, it improves strength, endurance, and recovery speed.
Usage protocol
Dosage: 2-3 times daily, 100-300 μg each time (2-6 mg per week), usually mixed at a 1:1 ratio with CJC-1295 Without DAC.
Injection method: Subcutaneous injection, can be administered at the same site or different sites as CJC-1295 Without DAC.
Cycle management: No "hormone break" required, but regular monitoring of GH and IGF-1 levels is necessary to avoid excessive secretion.
CJC-1295 Without DAC 5mg + IPA 5mg combination: Scientific ratio and synergistic effect
Combination advantages
Long-acting + short-acting coverage: CJC-1295 Without DAC provides the basic GH secretion, while IPA supplements the pulse peak to achieve all-day GH release.
Minimization of side effects: The specificity of IPA can counteract the possible increase in prolactin or edema caused by CJC-1295 Without DAC.
Ease of use: The pre-mixed 5mg formulation simplifies the dispensing process and reduces the risk of contamination.
Clinical data support
GH and IGF-1 levels: The study shows that combined use can increase GH concentration by 10 times within 6 days and IGF-1 level by 3 times within 9-11 days.
Improvement in body composition: The average body fat percentage of the subjects decreased by 5%, lean body mass increased by 3%, and muscle strength improved by 10-15%.
Safety: Common side effects include injection site reactions (pain, redness, swelling) and transient flushing. The incidence of serious adverse reactions (such as carpal tunnel syndrome, insulin resistance) is less than 1%.
Applicable population
Athletes and fitness enthusiasts: aiming for muscle growth, fat reduction, and rapid recovery.
Anti-aging seekers: hoping to improve sleep, bone density, and skin condition.
Patients with GH deficiency: as an adjunctive therapy (requires doctor's guidance).
Precautions
Contraindications: Prohibited for those allergic to the ingredients, patients with active cancer, and those with severe heart or kidney dysfunction.
Drug interactions: Avoid using together with glucocorticoids, insulin, or oral hypoglycemic drugs.
Monitoring indicators: Regularly test blood sugar, blood lipids, thyroid function, and perform pituitary MRI (for long-term users).
Risks and Controversies: Key to Scientific Use
Pituitary suppression: Long-term use at high doses may inhibit the body's own GH secretion function.
Metabolic disorders: In rare cases, it may cause hyperglycemia or abnormal lipid levels.
Legal risks: In most countries, CJC-1295 Without DAC and IPA have not been approved for human use and are only for research purposes.
Optimize usage strategies
Dose individualization: Start with a low dose (such as 1mg per day) and gradually adjust to the tolerated range.
Combined nutritional support: Supplement with protein, zinc, and vitamin D to enhance the effect of GH.
Cycle design: Adopt the "3 months of use + 3 months of rest" model to balance benefits and risks.
Conclusion
View the potential of peptide combinations rationally
The combination of CJC-1295 without DAC (5mg) + IPA (5mg) provides scientific evidence for muscle growth, fat reduction, and anti-aging through the synergistic effect of long-acting and short-acting substances. However, its use requires strict adherence to dosage guidelines and thorough assessment of individual health conditions. In the future, with the expansion of more clinical studies, this combination is expected to play a greater role in the medical field, but for now, a cautious attitude should be maintained to avoid abuse or over-reliance.
